Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is a phase I study. The purpose of this study is to see if it is safe and feasible to
give the participant cyclophosphamide (a type of chemotherapy), natural killer (NK) cells,
and an antibody called Hu3F8 as a treatment for neuroblastoma. NK cells are a type of white
blood cell.
Funding Source- FDA OOPD